Oxford Biomedica PLC Holding(s) in Company

RNS Number : 7665B

Oxford Biomedica PLC

01 February 2024

 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BDFBVT43

Issuer Name

OXFORD BIOMEDICA PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Institut Merieux SA

City of registered office (if applicable)

Lyon

Country of registered office (if applicable)

France

4. Details of the shareholder

Name	City of registered office	Country of registered office
Natixis	Paris	France

5. Date on which the threshold was crossed or reached

29-Jan-2024

6. Date on which Issuer notified

01-Feb-2024

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	6.151995	0.000000	6.151995	6149374
Position of previous notification (if applicable)	3.099950	0.000000	3.099950	3000000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00BDFBVT43	6149374	0	6.151995	0.000000
Sub Total 8.A	6149374		6.151995%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Institut Merieux SA	TSGH SAS	6.151995	0.000000	6.151995%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

TSGH SAS (a wholly owned subsidiary of Institut Merieux SA) holds the shares in Oxford Biomedica Plc through a securities account of the French corporate and investment bank, Natixis (the ''Shareholder''). Institut Merieux SA has control and discretion over the voting rights attaching to the shares of Oxford Biomedica Plc, which are held by the Shareholder, through its ownership of the equity of TSGH SAS.

12. Date of Completion

01-Feb-2024

13. Place Of Completion

United Kingdom

 

Contact name:	Natalie Walter
Contact phone number:	01865 783 000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

HOLUASNRSBUURAR